Lipid Based Immunotherapies
Duhn Therapeutics is a clinical-stage company advancing lipid-based cancer immunotherapies
Our mission is to bring new solutions to cancer patients by reshaping the immunological profile of their tumors
About Duhn Therapeutics
Duhn Therapeutics SAS, a clinical-stage company co-founded by Landmark BioVentures AG, and OM Pharma SA, a swiss based global biopharmaceutical company.
The lead program, DHN198, is a clinical-stage asset for solid cancers associated with or resulting from chronic non-resolved immunosuppressive inflammation.
Building upon years of collaboration with translational researchers and clinicians from the University of Bourgogne and the Georges François Leclerc Cancer Treatment Center (CGFL), Duhn Therapeutics is strategically located in Dijon, France, where it plans to conduct its in-house R&D operations in partnership with the Laboratory of Immunology and Cancer Immunotherapy (LIIC).
Duhn Therapeutics is part of the nexus of Landmark Bioventures.
Our Technology
DHN198 is a synthetic lipid analogue, originally discovered as part of OM Pharma’s foundational research on bacterial lysates. DHN198 is a clinical-stage drug candidate with a dual mechanism of action small molecule, acting as a TLR4 antagonist and TLR2 agonist with unique immunomodulating properties. In a phase 1 clinical trial with cohorts of healthy volunteers and refractory tumor patients, DHN198 showed it was well tolerated and had a favorable safety profile, with encouraging efficacy signals in patients.
This makes DHN198 and lipid-based immunotherapies developed around the science of therapeutic lipids promising candidates for reshaping the immunosuppresive environment of cancers.
Co-Founders - Executive Team
Jacques Bauer
PhD
Chief Scientific Officer
Chief Operating Officer
Zaki Sellam
MBA, Msc
Executive Chairman
-
20+ years of experience in Biotech
-
Expert in Immuno-Oncology Drug Development - created and developed several start-ups & signed more than 40 Deals
-
35+ years of experience in Biopharma
-
Former R&D Director at OM Pharma
-
Expert in drug discovery, drug development in oncology, immunology and metabolic diseases
Our Ecosystem & Partners
